Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Book Review
Book Reviews
Classics In Indian Medicine
Clinical Case Report
Clinical Case Reports
Clinical Research Methods
Clinico-pathological Conference
Eminent Indians in Medicine
Everyday Practice
Film Review
History of Medicine
Images In Medicine
Indian Medical Institutions
Letter from Bristol
Letter from Chennai
Letter From Ganiyari
Letter from Glasgow
Letter from London
Letter From Mumbai
Letter From Nepal
Medical Education
Medical Ethics
Medicine and Society
News From Here And There
Original Article
Original Articles
Review Article
Selected Summaries
Selected Summary
Short Report
Short Reports
Speaking for Myself
Speaking for Ourselve
Speaking for Ourselves
View/Download PDF

Translate this page into:

Clinical Case Reports
35 (
); 276-277

Transient Bell’s palsy following Covid-19 vaccination

Department of Internal Medicine, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi 110029, India
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

[To cite: Jagadeesan S, Khan U, Jain A. Transient Bell’s palsy following Covid-19 vaccination. Natl Med J India 2022;35:276–7.]


Bell’s palsy is described as an acute, unilateral mononeuropathy of the facial nerve resulting in partial or complete paralysis of the face with no identifiable cause. Although facial palsy is often idiopathic, its development soon after the BB-152 Covid vaccine is exceedingly rare. We report a patient with transient acute-onset unilateral infranuclear facial palsy following vaccination, after an exhaustive work-up for other common causes was negative. With no detectable aetiology the likelihood of an association of the Covid-19 vaccine and Bell’s palsy remains.


Bell’s palsy is the most common cause of peripheral facial nerve paralysis, presenting as acute, idiopathic, unilateral, and partial to complete paralysis of the facial muscles in a susceptible individual.1 The annual incidence of the disease is about 25 per 100 000 or 1 in 60 people in the entire life span.2 Although a relatively common entity, the actual pathogenic mechanism behind the disease is yet to be established. Neurological aftereffects including anosmia, headache, demyelinating illnesses especially Guillain–Barre syndrome, seizures and encephalopathy have been reported after the introduction of various vaccines against SARS-CoV-2. We report an elderly woman who developed Bell’s palsy following administration of the BB-152 vaccine.


A 62-year-old woman presented in early September 2021 to the medical emergency of our hospital with complaints of sudden-onset facial asymmetry and inability to close her left eyelid (Fig. 1). She suffered from no medical comorbid conditions except hypertension that was adequately controlled. She was not on any other medications. On further probing, she said she had taken the first dose of the BB-152 Covid-19 vaccine the evening before. She denied any history of ear pain or discharge, taste disturbances, neck or parotid swelling, and prior herpes elsewhere. There were no similar episodes in the past. She also denied any history of substance abuse.

FIG 1.: Face showing complete lower motor neuron facial palsy on day 2 of vaccination

On clinical examination, she was a moderately built and nourished woman with a body mass index (BMI) of 26 kg/m2 and was oriented well to time, place and person. Her haemodynamic parameters were within normal limits. There was no obvious rash. Cardiovascular, respiratory and abdominal examinations were unremarkable. Cranial nerve examination revealed an isolated left facial paralysis (House Brackmann, Grade 4)3 involving the upper half of the face. The rest of the neurological examination including the motor, sensory and cerebellar examination was unremarkable. Haematological and urinary investigations were normal for her age. A clinical diagnosis of vaccine-associated left infranuclear facial paralysis was made and she was started on low-dose prednisolone that was tapered over 4 weeks in consultation with an Otology specialist. By the second week of illness, she started noticing improvement and after 3 months, it had resolved completely.


It is known that a few Covid-19 vaccines have adverse events including the Oxford-AstraZeneca vaccine (ChAdOx1nCoV-19) from the UK4 and the Chinese Sinovac vaccine in Brazil. The American Neurological Association has reported (data from FARES/VARES) numerous cases of stroke, Guillain–Barre syndrome, acute transverse myelitis, acute disseminated encephalomyelitis (ADEM), and a few cases of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) although facial nerve palsy has been reported less commonly.5

The risk of acute-onset peripheral facial nerve palsy has been found to be increased especially in the immediate post-vaccination period. The cause of development of Bell’s palsy, in general, is still unclear although the activation of dormant herpes simplex virus in the geniculate ganglion attracts gravity, suggesting precedence of otalgia before the signs of facial palsy appear.6 The autoimmune theory in post-vaccination palsy suggests that the inactivated virus containing numerous viral antigens can alter the immune response in patients.7 Although hypertension-related neuropathy could theoretically cause Bell’s palsy, it is unlikely as her blood pressure was under control since the time of her diagnosis. No other cause was found in her.

The prognosis of the disease is excellent, with more than 80% improving spontaneously and completely as in our patient. Only around 5% of patients are left with either severe or residual facial paralysis necessitating physiotherapy and other cosmetic procedures.8 Further studies are needed to ascertain the temporality and causation factor of the BB-152 and other Covid-19 vaccines in Bell’s palsy so that early recognition and prompt treatment if required can be provided to avoid possible vaccine hesitancy among people.


Bell’s palsy following Covid-19 vaccination warrants attention for active surveillance and reporting of the former. This being reversible or treatable, we recommend that the pace of vaccination should continue keeping the risk–benefit ratio of vaccines in mortality prevention in Covid-19.

Conflicts of interest

None declared


  1. , , , , , . The etiology of Bell’s palsy: A review. J Neurol. 2020;267:1896-905.
    [Google Scholar]
  2. . Incidence of Bell’s palsy. Ann Otol Rhinol Laryngol Suppl. 1988;137:3-4.
    [Google Scholar]
  3. , , , . Facial nerve grading systems (1985–2002): Beyond the House–Brackmann scale. Otol Neurotol. 2002;23:767-71.
    [Google Scholar]
  4. . …but Europeans get cold feet amid vaccine controversy. New Sci. 2021;249:9.
    [Google Scholar]
  5. , , , , , , et al. Adverse events reported from COVID-19 vaccine trials: A systematic review. Indian J Clin Biochem. 2021;36:427-39.
    [Google Scholar]
  6. , , . Herpes zoster oticus: A rare clinical entity. Contemp Clin Dent. 2010;1:127-9.
    [Google Scholar]
  7. , , , , , . A systematic review of SARSCoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5:237.
    [Google Scholar]
  8. , , , , , , et al. Prognostic factors of Bell’s palsy and Ramsay Hunt syndrome. Medicine (Baltimore). 2017;96:e5898.
    [Google Scholar]
Show Sections